Association of aldehyde dehydrogenase 2 gene polymorphism with multiple oesophageal dysplasia in head and neck cancer patients

por Muto, M, Hitomi, Y, Ohtsu, A, Ebihara, S, Yoshida, S, Esumi, H
Publicado em 2000

Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma

por Ohtsu, A, Baba, H, Sakata, Y, Mitachi, Y, Horikoshi, N, Sugimachi, K, Taguchi, T
Publicado em 2000

Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial

por Kurokawa, Y, Boku, N, Yamaguchi, T, Ohtsu, A, Mizusawa, J, Nakamura, K, Fukuda, H
Publicado no ESMO Open (2016)

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours

por Doi, T, Ohtsu, A, Yoshino, T, Boku, N, Onozawa, Y, Fukutomi, A, Hironaka, S, Koizumi, W, Sasaki, T
Publicado em 2012

Clinicopathological differences between colonic and rectal carcinomas: are they based on the same mechanism of carcinogenesis?

por Konishi, K, Fujii, T, Boku, N, Kato, S, Koba, I, Ohtsu, A, Tajiri, H, Ochiai, A, Yoshida, S
Publicado em 1999

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

por Yamada, Y, Tahara, M, Miya, T, Satoh, T, Shirao, K, Shimada, Y, Ohtsu, A, Sasaki, Y, Tanigawara, Y
Publicado em 2008

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

por Koizumi, W, Tanabe, S, Saigenji, K, Ohtsu, A, Boku, N, Nagashima, F, Shirao, K, Matsumura, Y, Gotoh, M
Publicado em 2003

PD-010 Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer

por Kotani, D., Pashtoon, K., Cecchini, M., Shitara, K., Ohtsu, A., Ramanathan, R., Hochster, H., Grothey, A., Yoshino, T.
Publicado no Ann Oncol (2016)

Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus

por Kaneko, K, Ito, H, Konishi, K, Kurahashi, T, Ito, T, Katagiri, A, Yamamoto, T, Kitahara, T, Mizutani, Y, Ohtsu, A, Mitamura, K
Publicado em 2003

PD-038 Exposure-Response relationship of second-line ramucirumab in East Asian patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

por Kim, T.Y., Yen, C.-J., Al-Batran, S.-E., Gao, L., Ferry, D., Hsu, Y., Cheng, R., Orlando, M., Ohtsu, A.
Publicado no Ann Oncol (2016)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab

por Bando, H, Yoshino, T, Tsuchihara, K, Ogasawara, N, Fuse, N, Kojima, T, Tahara, M, Kojima, M, Kaneko, K, Doi, T, Ochiai, A, Esumi, H, Ohtsu, A
Publicado em 2011

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

por Doi, T, Takiuchi, H, Ohtsu, A, Fuse, N, Goto, M, Yoshida, M, Dote, N, Kuze, Y, Jinno, F, Fujimoto, M, Takubo, T, Nakayama, N, Tsutsumi, R
Publicado em 2012

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

por Kawamoto, Y, Tsuchihara, K, Yoshino, T, Ogasawara, N, Kojima, M, Takahashi, M, Ochiai, A, Bando, H, Fuse, N, Tahara, M, Doi, T, Esumi, H, Komatsu, Y, Ohtsu, A
Publicado em 2012

PD-014 Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030)

por Yoshino, T., Shinozaki, E., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., Tsuji, Y., Moriwaki, T., Esaki, T., Hamada, C., Tanase, T., Ohtsu, A.
Publicado no Ann Oncol (2016)

PD-013 Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE...

por Yoshino, T., Kuboki, Y., Nishina, T., Shinozaki, E., Yamazaki, K., Shitara, K., Okamoto, W., Kajiwara, T., Matsumoto, T., Tsushima, T., Mochizuki, N., Fukutani, M., Nakamoto, M., Hasegawa, H., Sugama, A., Nomura, S., Sato, A., Ohtsu, A.
Publicado no Ann Oncol (2016)

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated ga...

por Al-Batran, S.-E., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O. N., Kim, T.-Y., Cunningham, D., Rougier, P., Muro, K., Liepa, A. M., Chandrawansa, K., Emig, M., Ohtsu, A., Wilke, H.
Publicado no Ann Oncol (2016)

PD-025 RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment

por Tabernero, J., Mayer Robert, J., Ohtsu, A., Yoshino, T., Garcia-Carbonero, R., Pastorino, A., Peeters, M., Winkler, R., Makris, L., Wahba, M., Zaniboni, A., Shimada, Y., Yamazaki, K., Komatsu, Y., Hochster, H., Lenz, H.-J., Falcone, A., Tran, B., Van Cutsem, E.
Publicado no Ann Oncol (2016)

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

por Arnold, D, Fuchs, C S, Tabernero, J, Ohtsu, A, Zhu, A X, Garon, E B, Mackey, J R, Paz-Ares, L, Baron, A D, Okusaka, T, Yoshino, T, Yoon, H H, Das, M, Ferry, D, Zhang, Y, Lin, Y, Binder, P, Sashegyi, A, Chau, I
Publicado no Ann Oncol (2017)

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

por Yoshino, T., Cleary, J. M., Van Cutsem, E., Mayer, R. J., Ohtsu, A., Shinozaki, E., Falcone, A., Yamazaki, K., Nishina, T., Garcia-Carbonero, R., Komatsu, Y., Baba, H., Argilés, G., Tsuji, A., Sobrero, A., Yamaguchi, K., Peeters, M., Muro, K., Zaniboni, A., Sugimoto, N., Shimada, Y., Tsuji, Y., Hochster, H. S., Moriwaki, T., Tran, B., Esaki, T., Hamada, C., Tanase, T., Benedetti, F., Makris, L., Yamashita, F., Lenz, H.-J.
Publicado no Ann Oncol (2020)